Trial Profile
Long-Term Valcyte Therapy in Transplant Patients and the Development of Ganciclovir Resistant CMV.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalic inclusion disorders
- Focus Therapeutic Use
- 27 Oct 2009 New trial record